However, the gene therapy and liver transplantation have not been well established, and therefore LDL apheresis is the only available treatment in the clinical practice in general. Heterozygous FH requires aggressive drug therapy, and HMG-CoA reductase inhibitors (statins) are effective. A combination of statins and anion-exchange resin (resin) is effective for the management of severe hypercholesterolemia of FH. This disease needs particularly intensive treatment among variations of primary hyperlipidemia. Also, as the disease appears by clear dominant inheritance and affects half the family members, familial management is important.
Familial Combined Hyperlipidemia (FCHL)
FCHL is an inherited hyperlipidemia of phenotype a, during the clinical course and b is the most frequent showing various phenotype such as a, b, or . The relatives of first-degree consanguinity shows also various phenotypes a, b, or . Diet therapy is effective in FCHL. Although Goldstein et al. 1) reported the disease to be inherit based on a single gene abnormality, FCHL may be induced by excessive VLDL synthesis and secretion secondary to the increased portal influx of free fatty acids due to multible gene abnormalities or visceral fat accumulation recently. The lipoprotein abnormaties in FCHL are characterized by an excess of apoprotein B content to the LDL-C level caused by excessive VLDL synthesis and secretion due to an increased influx of free fatty acids and thus an elevation in small dense LDL, which is rich in TG with a smaller particle size and is more likely to be oxidized than ordinary LDL. Also, a multigenetic basis that facilitates the induction of hyperlipidemia by acquired factors such as hypernutrition is considered to underlie the development of such a condition.
Conventionally, the diagnostic criteria proposed by the Study Group of Primary Hyperlipidemia, a
Primary Hyperlipidemia and Coronary Artery Disease
Gene mutations have been identified in some types of hyperlipidemia primarily due to genetic causes but not in others. Coronary artery disease (CAD) is likely to develop in familial hypercholesterolemia (FH) 1, 2) , familial combined hyperlipidemia 3, 4) , and familial type hyperlipidemia among the variations of genetically-induced hyperlipidemia 5) . Table 1 shows diagnostic criteria for these disorders [6] [7] [8] . These variations of hyperlipidemia, particularly FH, require more stringent management.
Familial Hypercholesterolemia (FH)
FH is an autosomal dominant disease characterized by 3 major manifestations: marked hypercholesterolemia, tendinous xanthoma, and early-onset coronary arteriosclerosis. Although homozygous FH (homo FH) is a rare disease observed in 1 in about 1 million people, heterozygous FH (hetero FH) is much more common, affecting 1 in every 500 people. Elevation of LDL-cholesterol in FH is caused by mutations of the LDL receptor gene, and more than 40 types of mutations have been reported so far in Japan. Homozygous FH patients show a very high TC level of 500 mg/dL or above, and without treatment, are likely to develop fatal juvenile CAD. Males with heterozygous FH often develop myocardial infarction in about 30 years of age, but females with heterozygous FH rarely develop myocardial infarction before the age of 50 years 2) . While the treatment of patients with homozygous FH should be started in the childhood (on detection), males with heterozygous FH should be going to be treated after the age of about 20 years, and females with heterozygous FH after the age of 30 years, in principle. Treatment for homozygous FH includes LDL apheresis, liver transplantation, and LDL receptor gene therapy.
Refractory Disease Specified by the Ministry of Health and Welfare 6, 7) were used for the diagnosis of FCHL, and it requires detailed investigation of the family history. However, it is not so eary inprimary care to investigate as the family history. Therefore, new diagnostic criteria were established by the Study Group of ment of this disease, and statins and fibrates are effective among drugs.
Familial Type Hyperlipidemia
This disease occurs on the basis of the apoprotein E2/2 genotype (infrequently apoprotein E deficiency) and is characterized by high-remnant lipoprotein and an early onset of CAD. Type hyperlipidemia has been reported to be frequently complicated by CAD in Japanese 9) . Since this hyperlipidemia responds well to therapy, early diagnosis and treatment are extremely important. Lifestyle modification with dietary therapy as a core and drug therapy using fibrates or nicotinic acid derivatives are effective.
